National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology

Keith L. Davis; Sonia Marie Thomas; Lon S Schneider; Pierre N Tariot; Constantine G Lyketsos; Karen S Dagerman; Keith L. Davis; Sonia Thomas; John K Hsiao; D V Jeste; I R Katz; J T Olin; B G Pollock; P V Rabins; R A Rosenheck; G W Small; Barry D Lebowitz; Jeffrey A Lieberman

National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)

Alzheimer disease trial methodology

Schneider, L. S., Tariot, P. N., Lyketsos, C. G., Dagerman, K. S., Davis, K. L., Davis, S., Hsiao, J. K., Jeste, D. V., Katz, I. R., Olin, J. T., Pollock, B. G., Rabins, P. V., Rosenheck, R. A., Small, G. W., Lebowitz, B., & Lieberman, J. A. (2001). National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. American Journal of Geriatric Psychiatry, 9(4), 346-360. https://doi.org/10.1097/00019442-200111000-00004

Copy citation

Abstract

The authors describe the development of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) protocol for Alzheimer disease (AD), a trial developed in collaboration with the National Institute of Mental Health (NIMH), assessing the effectiveness of atypical antipsychotics for psychosis and agitation occurring in AD outpatients. They provide an overview of the methodology utilized in the trial as well as the clinical-outcomes and effectiveness measures that were implemented.